Otsuka Pharmaceutical Co., Ltd.

4:15 PM - 4:30 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104B
Our commercial flagship products Rexulti, Abilify Maintena, and Jynarque have established Otsuka as a global leader in the specialty fields of CNS and nephrology. We are also looking to enter the (rare) Immunology space, and are highly interested in partnership opportunities to strengthen our global pipeline, in order to bring truly differentiated drugs to market which have the potential to make a deep and lasting impact on patients' lives.

We are looking for preclinical to clinical stage compounds and are also interested in robust IND generation platforms.

In addition to the above global licensing targets, Otsuka is seeking for CV, GI, Ophth, Derma and Haemato-Oncology opportunities for Asia (incl. Japan) / Haemato-Oncology, Endocrinology and Rare (Focus on Specialty HCPs) for Europe to leverage our strong development and commercialization capabilities in these territories. To consider such regional partnerships, we would expect programs to have demonstrated compelling human PoC.
Tokyo Stock Exchange (Prime)
Company Type:
Publicly Traded Company
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Multiline Global Biopharma
Lead Product in Development:
Sibeprenlimab, Centanafadine, Ulotaront, SEP-4199, AVP-786
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
Sr. Manager, Global Business Development
Otsuka Pharmaceutical Co., Ltd.